1. Jasovich A, Curcio D, Bustos J, et al. Frecuencia de Streptococcus pneumoniae Penicilina-Resistente (SpR) en adultos con Neumonía Adquirida en la Comunidad (NAC): Racionalidad de los Esquemas Terapéuticos Empíricos Basados en los Sistemas de Vigilancia de Resistencia Bacteriana. X Congreso Panamericano de Infectología. Guadalajara, México 2001, Abst 59.
2. Avellaneda B, Juárez J, de Mier C, et al. Sensibilidad antibiótica en neumococos resistentes (NRP) y sensible a penicilina (NSP). 29º Congreso Argentino de Medicina Respiratoria. Buenos Aires, Argentina 2001. Abst 72.
3. Casellas JM. Epidemiology of bacterial incidence and resistance in community acquired respiratory tract infection in South America. 9th International Congress on Infectious Disease. Buenos Aires 2000; Abstr. 3.002.
4. Patel T, Desai R, Duff J, et al. Comparison of grepafloxacin (GFX) with clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP) [abstract LM- 69]. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997.
5. Moola S, Hagberg L, Churchyard A, et al. Comparison of grepafloxacin with clarithromycin in the treatment of community- acquired pneumonia (CAP) [abstract L-113]. In: Program and abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.